Simply Wall St.
Insider Spends US$99k Buying More Shares In Biomea Fusion
📊
AI Sentiment
Positive
7/10
- Home
- BMEA
BMEA
Biomea Fusion Inc.
as of 12-12-2025 4:00pm EST
$1.41
$0.11
-7.24%
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
Chart Type:
Time Range:
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | SAN CARLOS |
| Market Cap: | 96.9M | IPO Year: | 2021 |
| Target Price: | $8.71 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.20 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.87 - $6.30 | Next Earning Date: | 11-04-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered BMEA Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 68.71%
68.71%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Biomea Fusion Inc. (BMEA)
Hitchcock Michael J.M.
Buy
Interim CEO
BMEA Dec 2, 2025
Avg Cost/Share
$0.99
Shares
100,000
Total Value
$99,180.00
Owned After
115,000
SEC Form 4
Erdtmann Rainer M
Buy
See Remarks
BMEA Dec 1, 2025
Avg Cost/Share
$1.05
Shares
10,000
Total Value
$10,500.00
Owned After
693,027
SEC Form 4
Erdtmann Rainer M
Buy
See Remarks
BMEA Nov 28, 2025
Avg Cost/Share
$1.10
Shares
40,000
Total Value
$44,052.00
Owned After
693,027
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Hitchcock Michael J.M. | BMEA | Interim CEO | Dec 2, 2025 | Buy | $0.99 | 100,000 | $99,180.00 | 115,000 | |
| Erdtmann Rainer M | BMEA | See Remarks | Dec 1, 2025 | Buy | $1.05 | 10,000 | $10,500.00 | 693,027 | |
| Erdtmann Rainer M | BMEA | See Remarks | Nov 28, 2025 | Buy | $1.10 | 40,000 | $44,052.00 | 693,027 |
Latest Biomea Fusion Inc. News
BMEA Breaking Stock News: Dive into BMEA Ticker-Specific Updates for Smart Investing
GlobeNewswire
Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025
📈
AI Sentiment
Highly Positive
8/10
Compare BMEA vs Leading Stocks
See how BMEA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "BMEA Biomea Fusion Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.